Filter
Therapeutic AreaRegionDeal TypeNon Pharma
Apply Filters
July 2008

Exclusive Advisor, Listing Sponsor and Sole Bookrunner for cancer diagnostic specialist Ipsogen.

€ 11.7m Initial public offering.
November 2007

Exclusive Financial Advisor to NASDAQ-listed Exelixis (EXEL) in completing the divestiture of their subsidiary CRO Artemis GmbH to Taconic (TAC).

€ 50m Upfront and milestones and earn-outs.
August 2006

Divestiture of Pharmaton SA, Lugano and Boehringer Ingelheim’s worldwide Natural Health Phyto-based Nutraceuticals, Vitamins and Mineral Supplements to Amway.

Undisclosed terms.
December 2005

Completed divestiture of a broad-spectrum antibiotic (“Romifidine”) for feed use in Animal Health.

Undisclosed terms.
December 2004

Completed the 100% acquisition of German respiratory medical devices company Steag MicroParts GmbH, Dortmund.

€ 50m Total enterprise value.
May 2004

Completed acquisition of ID Lelystad’s Animal Health vaccine business.

Undisclosed terms.
November 2003

Completed acquisition of Novartis’s OTC Laxative brand Dulcolax.

€ 80m Upfront and milestone purchase price.
March 2003

Exclusive financial advisor to MorphoSys in signing collaboration partnership with Boehringer Ingelheim.

€ 15m Upfront payment.
October 2001

Exclusive financial advisor to Teva in the acquisition of German Specialty Generics Company AWD Pharmaceuticals.

Undisclosed terms.
September 2001

Lead Financial advisor to Bayer AG in their preparation of the acquisition of Aventis CropScience and completion of a detailed fairness opinion on alternative strategic options.

Undisclosed terms.
June 2001

Exclusive financial advisor to Teva in the issuance of a convertible bond offering.

US$ 500m Total Bond Value.
June 1999

Exclusive Financial Advisor in the acquisition of DSM N.V.‘s Transparent Sheet Business, a cross-border transaction involving two production sites.

€ 400m Total enterprise value.